Rephonic
Artwork for BiotechTV

BiotechTV - News

BiotechTV
FDA
Biotech
Obesity
Clinical Trials
Alzheimer's Disease
Parkinson's Disease
Biotechnology
Breast Cancer
Mergers and Acquisitions
Car-T Therapy
Oncology
Artificial Intelligence
Multiple Myeloma
Ulcerative Colitis
Immunology
TYK2
Gene Editing
Gene Therapy
Abivax
Takeda

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

PublishesDailyEpisodes485Founded2 years ago
Number of ListenersCategories
Life SciencesScience

Listen to this Podcast

Artwork for BiotechTV

Latest Episodes

He describes the biomarkers that researchers and investigators have been using, and how large pharma companies like Lilly and Novo Nordisk have begun to embrace the field. Plus, the logevity component Insilico has built into its IPF trials, and what ... more

CEO Markus Warmuth walks us through the data and provides a broader update on the pipeline progress at Monte Rosa and for the field of degraders and molecular glues more broadly.

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.

Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe.

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

Stefanie Fluckiger
Chief Executive, TOLREMO Therapeutics
TOLREMO Therapeutics
Episode: From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
Sascha Oliver Bucher
Co-founder and partner, Forty51 Ventures
Forty51 Ventures
Episode: From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
Jean Cui
Scientific founder, President and CEO of Blossom Hill Therapeutics
Blossom Hill Therapeutics
Episode: HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs
Paul Peter Tak
CEO of Candel Therapeutics
Candel Therapeutics
Episode: HCW 2026: As it approaches a BLA filing for its viral immunotherapy in prostate cancer, Candel has published its pivotal phase 3 data in Lancet Oncology and presented extended data at AUA
Andres Maldonado
Senior biotech analyst
HC Wainwright & Co.
Episode: HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology
Niels Riedemann
Founder and CEO of InflaRx
InflaRx
Episode: HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune
Pascal Prigent
CEO of Genfit
Genfit
Episode: HCW 2026: GENFIT has developed a blood based test for MASH - its CEO believes the MASH market has arrived. "If you believe in Mash, you have to believe in a diagnostic."
Ben Oakes
Co-founder and CEO of Scribe Therapeutics
Scribe Therapeutics
Episode: HCW 2026: Scribe Therapeutics, which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9
Chris Peetz
CEO of Mirum Pharmaceuticals
Mirum Pharmaceuticals
Episode: HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader

Host

Brad
Brad, on-air host with multiple segments including BiotechTV - News and biotech innovation coverage.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

From Basel: With two products on the market with momentum and a key pipeline asset in a P3, Basilea has become a world leader in the development of therapies for bacterial and fungal infections
Q: Nice jump in the share price. What got people excited there?
The growth was driven by higher revenues from Basilea's anti-infective portfolio, a strengthened guidance, and visible progress in the phase 3 portfolio, which together created a compelling narrative about the company's future trajectory.
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
Q: What are the next steps for TT125-802 in clinical development?
We will move to combination therapy, pairing TT125-802 with an EGFR inhibitor to explore deeper, longer responses in patients with EGFR-mutant lung cancer, starting with Osimertinib to test whether the safety and efficacy profile improves when the target pathway is inhibited in parallel with CBP/p300 inhibition.
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
Q: What were the phase one results you presented at the lung cancer conference?
The phase one data came from 45 patients with solid tumors; despite an initial all-comers cohort, we enriched for lung cancer and observed durable responses and tumor shrinkage in several resistant lung cancer subtypes, including both EGFR-mutant and KRAS-mutant forms, indicating meaningful anti-tumor activity of TT125-802 as a monotherapy.
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
Q: You work on cancer resistance and target CBP/p300. Can you explain the mechanism and how your approach differs from first-generation CBP inhibitors?
The strategy is to target transcriptional addiction and reprogramming in cancer by hitting the same CBP/p300 domain but with a different chemistry and a phenotypic start, which avoids the safety-limiting thrombocytopenia seen with earlier CBP inhibitors while still enabling deeper and longer responses in resistant tumors.
HCW 2026: BlossomHill IPO'd last month to tackle precision oncology, with a Scientific Founder / CEO who already has a hall of fame record in the space - Jean Cui walks us through her programs
Q: Could you explain the PanKRAS strategy and how it differs from tricomplex approaches?
The discussion covers the shift from tricomplex inhibitors to allosteric pocket inhibitors that rigidify KRAS and shut down signaling, with emphasis on long-lasting, durable efficacy and the development of a pseudo-irreversible pharmacology in pancreatic cancer.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About BiotechTV

What is BiotechTV about and what kind of topics does it cover?

BiotechTV's news-focused episodes center on on-the-ground reporting from biotech hubs, with detailed conversations around company strategy, clinical data, regulatory developments, and industry dynamics. Frequent guests are biotech executives, founders, investors, scientists, and policy or communications leaders who offer firsthand insight into programs, financing, FDA decisions, and innovation pipelines. Notable strengths include high-signal interviews with senior leaders discussing IPOs, novel platforms, and strategic pivots, plus timely coverage of conferences and breaking industry news. The show likely appeals to biotech executives, investors, researchers, and professionals who want practical context for emerging therapies, diagnostic to... more

Where can I find podcast stats for BiotechTV?

Rephonic provides a wide range of podcast stats for BiotechTV. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to BiotechTV and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does BiotechTV get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for BiotechTV, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for BiotechTV?

Rephonic provides comprehensive predictive audience data for BiotechTV, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does BiotechTV have?

To see how many followers or subscribers BiotechTV has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to BiotechTV?

These podcasts share a similar audience with BiotechTV:

1. Biotech Hangout
2. BioCentury This Week
3. The Readout Loud
4. The Long Run with Luke Timmerman
5. BioVenture VoiCes with Chris Garabedian

How many episodes of BiotechTV are there?

BiotechTV launched 2 years ago and published 485 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact BiotechTV?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for BiotechTV?

Rephonic pulls ratings and reviews for BiotechTV from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for BiotechTV?

Rephonic provides full transcripts for episodes of BiotechTV. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on BiotechTV?

Recent guests on BiotechTV include:

1. Stefanie Fluckiger
2. Sascha Oliver Bucher
3. Jean Cui
4. Paul Peter Tak
5. Andres Maldonado
6. Niels Riedemann
7. Pascal Prigent
8. Ben Oakes

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days